High-dose dexamethasone treatment for SARS-COV-2 : EARLY TREATMENT STRATEGY WITH HIGH-DOSE VERSUS STANDARD-DOSE DEXAMETHASONE IN PATIENTS WITH SARS-COV-2 PNEUMONIA (COVID-19). - PREDEXACOV-01

Media Type:

Clinical Trial

Year of Publication:

2021

Publication:

2021

Contained In:

WHO International Clinical Trials Registry Platform - (2021) vom: 07. Sept. To Main Record - year:2021

Language:

Unbestimmt

Links:

Volltext [kostenfrei]

Keywords:

610
Medical Condition: Adult patients with SARS-CoV-2 infection (COVID19) requiring hospital admission for pneumonia. Who present pcr = 66 mg/L and =150 mg/L at inclusion or Pandemic score [13] on admission > 200 with pcr 9.7-149 mg/L at inclusion. WHO scale level 4 [14], with need for oxygen therapy in NG = 1 lpm to maintain saturation = 94%. ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Phase: Phase 3
Recruitment Status: Authorised-recruitment may be ongoing or finished
Study Type: Interventional

Notes:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 26-05-2021, Last updated: 2021-09-13

PPN (Catalogue-ID):

WHO007892438